After ~10 months of relative quiescence we've started to see some striking evolution of SARS-CoV-2 with a repeated evolutionary pattern in the SARS-CoV-2 variants of concern emerging from the UK, South Africa and Brazil. 1/19
In SARS-CoV-2, the viral spike protein and in particular the receptor binding domain (RBD) is a locus for important viral evolution and is the primary target for the human immune response (figure from science.sciencemag.org/content/367/64…). 2/19
There had been little evolution in the RBD until ~Oct 2020 when we saw RBD mutations start to spread. Perhaps chief among mutations of interest are E484K and N501Y which mutate nearby sites in the RBD. The evolution of these sites can be seen here: nextstrain.org/ncov/global?c=…. 3/19
E484K and N501Y have occurred repeatedly on the evolutionary tree of the virus representing convergent evolution. Many 484K and 501Y instances are due to the three variants of concern, but there are other 484K and 501Y viruses that are not due to these variants. 4/19
The above figure is a "root-to-tip" plot showing number of mutations in sampled viruses against date of collection. The dashed line represents average accumulation of mutations of about 1 mutation every 2 weeks. The 501Y.V1 variant stands out here with additional mutations. 6/19
Like 501Y.V1, both 501Y.V2 and 501Y.V3 also appear to possess "extra" mutations beyond what's seen in most circulating viruses. And importantly, these variant viruses show repeated convergent evolution including spike sites 417, 484, 501 and the ORF1ab deletion. 9/19
Extra protein coding mutations localized to spike alongside convergent evolution are hallmarks of adaptive evolution. So, what's going on here? 10/19
My (highly speculative!) hypothesis is that the emergence of these variant viruses arises in cases of chronic infection during which the immune system places great pressure on the virus to escape immunity and the virus does so by getting really good at getting into cells. 11/19
This results in the observed increased viral load (medrxiv.org/content/10.110…) and greater transmissibility (gov.uk/government/pub…) of 501Y.V1 / B.1.1.7, but importantly this is not due to population-level selection for antigenic drift or faster transmission. 12/19
Instead it's a knock-on effect of the reactor of evolution occurring in rare chronic infections and then spillover from these infections into the greater population. 13/19
This hypothesis of increased binding and cell entry as mechanism for immune evasion was expressed previously in the context of seasonal influenza by @SCOTTeHENSLEY in science.sciencemag.org/content/326/59…. 14/19
Hints that these emergence events are related to chronic infections come from multiple sources. First off, we have direct sequencing of viruses from chronic infections that show rapid evolution (figure from @binachoimd et al nejm.org/doi/full/10.10…). 15/19
Indeed, this particular chronic infection evolved some of the exact same mutations seen in these variant viruses including 484K, 501Y and a 144 deletion. 16/19
Additionally, @K_G_Andersen pointed me to work with coronavirus in mouse models showing that deletions are associated with chronic infections (ncbi.nlm.nih.gov/pmc/articles/P…). It's striking that the 3 AA deletion in ORF1ab is so far a hallmark of SARS-CoV-2 variant viruses. 17/19
Finally, the exceptionally long branch leading to 501Y.V1 is difficult to explain by a chain of infections given that genomic surveillance by @CovidGenomicsUK is sequencing approximately ~5% of cases; surveillance should have picked up intermediates if they existed. 18/19
Again, this hypothesis is highly speculative at this point, but separately, the fact that we've observed 3 variants of concern emerge since September suggests that there are likely more to come. 19/19
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Currently, the US is reporting about 54k daily cases of COVID-19 (16 per 100k per capita) and the UK is reporting about 4k (6 per 100k). This seems comfortingly low compared to even this summer's BA.5 wave and let alone last winter's BA.1 wave. Figure from @OurWorldInData. 1/16
However, at this point, nearly all infections will be in individuals with prior immunity from vaccination or infection and this combined with a roll back in testing makes it unclear how to interpret current case counts compared to previous time periods. 2/16
We're interested in the case detection rate or the ratio of underlying new infections compared to reported cases. Throughout much of 2020 and 2021, I had a working estimate of 1 infection in ~3.5 getting reported as a case. 3/16
Largely through partial immune escape, lineage BA.5 viruses resulted in sizable epidemics throughout much of the world. However, in most countries these epidemics are now beginning to wind down. What do we expect after BA.5? 1/10
Lineage BA.2.75 (aka 'Centaurus') has been high on watch lists due to sustained increase in frequency in India combined with the presence of multiple mutations to spike protein. We now have enough sampled BA.2.75 viruses from outside India to make some initial conclusions. 2/10
If we look at frequency data we see sustained logistic growth of BA.2.75 in India, Japan, Singapore and the US. Critically, in India it is clearly displacing BA.5. 3/10
Based on the experience in winter 2020/2021, seasonal influence on SARS-CoV-2 transmission is quite clear, but much of the Northern Hemisphere is currently experiencing large summer epidemics driven the spread of evolved BA.5 viruses. 1/11
It's necessarily fraught to try to make predictions of seasonal circulation patterns going forwards, but we can gain some intuition from simple epidemiological models. 2/11
In particular, we can use an SIRS system in which individuals go from Susceptible to Infected to Recovered, and then return to the Susceptible class due to immune waning / antigenic drift of the virus. 3/11
There seems to be a worry that telling people we've exited the "pandemic phase" will lead to further reduced precautions. As always however, I think it's best not to conduct messaging for intended behavioral effect and just try to make scientifically accurate statements. 1/5
Given vaccination and infection, the US and global population now has widespread immunity to SARS-CoV-2 and deaths per-infection are about 10 times lower than they were pre-immunity in 2020 with a ballpark IFR of 0.05% (though this will vary by immunity and age demographics). 2/5
You can see this reduction in mortality rate in looking at projections of deaths from lagged-cases keyed to early case fatality rate. 3/5
The @US_FDA VRBPAC committee will be meeting tomorrow to discuss variant-specific COVID-19 vaccines (fda.gov/advisory-commi…). Based on present observations, I would argue that the most important metric to optimize are titers against BA.4/BA.5 viruses. 1/10
We've seen repeated replacement of SARS-CoV-2 variants during 2022, first of Delta by Omicron BA.1 and then by sub-lineages of Omicron, with BA.2 replacing BA.1 and now with BA.4/BA.5 replacing BA.2. 2/10
Viruses have been evolving to be higher fitness through both increases in intrinsic transmissibility (seen in BA.2 vs BA.1) as well as escape from existing population immunity (seen in Omicron vs Delta as well as BA.4/BA.5 vs BA.2). 3/10
Global monkeypox confirmed and suspected cases compiled by @globaldothealth show initial rapid increase as case-based surveillance comes online, followed by slower continued growth. 1/10
This is data from github.com/globaldothealt… and has had a 7-day smoothing applied and all y-axes are shown on a log scale. 2/10
If we focus on the last 11 days, we can see steady exponential growth in global cases with a ~7.7 day doubling. 3/10